{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    46,
    57,
    59,
    60,
    61,
    62,
    63,
    64,
    65,
    66,
    67,
    68
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "The point at which a subject is assigned to a treatment arm and is no longer considered a screen failure.",
        "anchorType": "Randomization",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 40,
        "sourceText": "Screen Failure: A subject who is screened but is not treated or randomized",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_1",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 50,
        "sourceText": "Baseline visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 20,
        "sourceText": "Screening visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "Informed Consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P21D",
        "endOffset": "-P1D",
        "sourceText": "Days \n-21 to -1"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "P18D",
        "endOffset": "P90D",
        "sourceText": "Week 18 to Week 90"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "startOffset": "P90D",
        "endOffset": "P96D",
        "sourceText": "Week 90 to Week 96"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "startOffset": "P12D",
        "endOffset": "P96D",
        "sourceText": "Week 12 to Week 96"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "startOffset": "P12D",
        "endOffset": "P96D",
        "sourceText": "from Week 12 to Week 96"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "screening phase"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "3 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P6W",
        "exitCondition": "null",
        "sourceText": "q6w Every 6 weeks"
      },
      {
        "id": "rep_llm_2",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P8W",
        "exitCondition": "null",
        "sourceText": "q8w Every 8 weeks"
      },
      {
        "id": "rep_llm_3",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P12W",
        "exitCondition": "null",
        "sourceText": "q12w Every 12 weeks"
      },
      {
        "id": "rep_llm_4",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "null",
        "exitCondition": "null",
        "sourceText": "Requirement to apply the same pregnancy testing in both arms, throughout the study"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "TREATMENT",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Required Assessment",
          "Screening",
          "Baseline",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'Subject experiences AE requiring discontinuation', 'path': ['DISCONTINUATION_OF_STUDY_TREATMENT', 'EARLY_TERMINATION_VISIT']}, {'condition': 'Subject is lost to follow-up', 'path': ['LOST_TO_FOLLOW_UP_PROCEDURES']}, {'condition': 'Withdrawal of informed consent', 'path': ['WITHDRAWAL_OF_CONSENT_PROCEDURES']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Vital Sign",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "EPISODE signals: 1; SINGLE signals: 2"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant Medication",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2; SINGLE signals: 2"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Imaging",
        "executionType": "Recurring",
        "rationale": "WINDOW signals: 1; EPISODE signals: 1; RECURRING signals: 4"
      },
      {
        "activityId": "Epro",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2; SINGLE signals: 1"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "The screening phase is a one-time assessment period to determine eligibility prior to randomization."
      },
      {
        "activityId": "Randomization",
        "executionType": "Single",
        "rationale": "Treatment assignment occurs as a single event at the start of the study."
      },
      {
        "activityId": "Study Treatment Administration",
        "executionType": "Single",
        "rationale": "The protocol describes a 96-week study with scheduled doses of brolucizumab or laser at specific study visits."
      },
      {
        "activityId": "Safety and Efficacy Assessments",
        "executionType": "Single",
        "rationale": "Assessments are scheduled to repeat at multiple study visits throughout the 96-week duration."
      },
      {
        "activityId": "Dose Modification",
        "executionType": "Single",
        "rationale": "Section 6.5 indicates conditional workflows for adjusting treatment based on specific clinical criteria or safety findings."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_before",
        "text": "a. Informed consent must be obtained prior to any study-specific procedures.",
        "footnoteId": "fn_1",
        "structuredCondition": "sequence.must_precede(informed_consent, all_study_procedures)",
        "appliesToActivityIds": [
          "All study-specific procedures"
        ],
        "sourceText": "a. Informed consent must be obtained prior to any study-specific procedures."
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. Includes history of primary diagnosis, including type of diabetes and PDR.",
        "footnoteId": "fn_2",
        "structuredCondition": "procedure.include(primary_diagnosis_history, [diabetes_type, PDR])",
        "appliesToActivityIds": [
          "Medical History"
        ],
        "sourceText": "b. Includes history of primary diagnosis, including type of diabetes and PDR."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c. Vital signs include blood pressure and pulse rate.",
        "footnoteId": "fn_3",
        "structuredCondition": "procedure.include(vital_signs, [blood_pressure, pulse_rate])",
        "appliesToActivityIds": [
          "Vital Signs"
        ],
        "sourceText": "c. Vital signs include blood pressure and pulse rate."
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. BCVA to be assessed by masked certified personnel using ETDRS charts.",
        "footnoteId": "fn_4",
        "structuredCondition": "procedure.method(BCVA, [masked_personnel, ETDRS_charts])",
        "appliesToActivityIds": [
          "BCVA"
        ],
        "sourceText": "d. BCVA to be assessed by masked certified personnel using ETDRS charts."
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "e. IOP measurement to be performed in both eyes; post-injection IOP measurement within 60 minutes for study eye.",
        "footnoteId": "fn_5",
        "structuredCondition": "timing.within(IOP_measurement, injection, PT60M)",
        "appliesToActivityIds": [
          "IOP measurement"
        ],
        "sourceText": "e. IOP measurement to be performed in both eyes; post-injection IOP measurement within 60 minutes fo"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "f. 7-field CFP and FA images to be evaluated by the Central Reading Center (CRC).",
        "footnoteId": "fn_6",
        "structuredCondition": "procedure.evaluator(CFP_FA_images, Central_Reading_Center)",
        "appliesToActivityIds": [
          "7-field CFP",
          "FA images"
        ],
        "sourceText": "f. 7-field CFP and FA images to be evaluated by the Central Reading Center (CRC)."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "h. Disease activity assessment (DAA) used to determine treatment interval extension or reduction.",
        "footnoteId": "fn_8",
        "structuredCondition": "decision.use(DAA, treatment_interval_adjustment)",
        "appliesToActivityIds": [
          "Disease activity assessment"
        ],
        "sourceText": "h. Disease activity assessment (DAA) used to determine treatment interval extension or reduction."
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "i. PRP treatment may be split into 2-4 sessions as needed up to Week 12.",
        "footnoteId": "fn_9",
        "structuredCondition": "frequency.split(PRP_treatment, 2, 4).before(W12)",
        "appliesToActivityIds": [
          "PRP treatment"
        ],
        "sourceText": "i. PRP treatment may be split into 2-4 sessions as needed up to Week 12."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_at",
        "text": "j. End of Study (EOS) visit to be performed at Week 96 or at early discontinuation.",
        "footnoteId": "fn_10",
        "structuredCondition": "timing.at(EOS, [W96, early_discontinuation])",
        "appliesToActivityIds": [
          "End of Study visit"
        ],
        "sourceText": "j. End of Study (EOS) visit to be performed at Week 96 or at early discontinuation."
      },
      {
        "id": "fn_cond_10",
        "conditionType": "timing_before",
        "text": "1. Signed informed consent must be obtained prior to participation in the study.",
        "footnoteId": "fn_11",
        "sourceText": "1. Signed informed consent must be obtained prior to participation in the study."
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "2. Patients ≥ 18 years of age at Screening.",
        "footnoteId": "fn_12",
        "structuredCondition": "eligibility.age >= 18",
        "appliesToActivityIds": [
          "Screening"
        ],
        "sourceText": "2. Patients ≥ 18 years of age at Screening."
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "3. Participant cooperation sufficient for adequate fundus photographs and retinal images.",
        "footnoteId": "fn_13",
        "sourceText": "3. Participant cooperation sufficient for adequate fundus photographs and retinal images."
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "4. Patients diagnosed with type 1 or 2 DM, and HbA1c ≤ 12% at Screening.",
        "footnoteId": "fn_14",
        "structuredCondition": "eligibility.and(diagnosis(DM_type_1_or_2), HbA1c <= 12)",
        "appliesToActivityIds": [
          "Screening"
        ],
        "sourceText": "4. Patients diagnosed with type 1 or 2 DM, and HbA1c ≤ 12% at Screening."
      },
      {
        "id": "fn_cond_14",
        "conditionType": "timing_before",
        "text": "5. Any medication administered for the management of DM should be stable within 3 months prior to randomization and is expected to remain stable during the course of the study, as medically acceptable. Study eye",
        "footnoteId": "fn_15",
        "structuredCondition": "eligibility.stable_medication(DM, P3M)",
        "appliesToActivityIds": [
          "Randomization"
        ],
        "sourceText": "5. Any medication administered for the management of DM should be stable within 3 months prior to ra"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "6. PDR as assessed by the investigator using standard or wide-field CFP and FA, with no evidence of previous PRP, and that requires treatment with either anti-VEGF or PRP in the opinion of the investigator.",
        "footnoteId": "fn_16",
        "sourceText": "6. PDR as assessed by the investigator using standard or wide-field CFP and FA, with no evidence of "
      },
      {
        "id": "fn_cond_16",
        "conditionType": "general",
        "text": "7. BCVA ≥ 34 ETDRS letters (Snellen equivalent 20/200) at Screening and Baseline.",
        "footnoteId": "fn_17",
        "structuredCondition": "eligibility.BCVA >= 34",
        "appliesToActivityIds": [
          "Screening",
          "Baseline"
        ],
        "sourceText": "7. BCVA ≥ 34 ETDRS letters (Snellen equivalent 20/200) at Screening and Baseline."
      },
      {
        "id": "fn_cond_17",
        "conditionType": "general",
        "text": "8. Presence of amblyopia, amaurosis, or ocular disorders in the fellow eye with BCVA < 20/200 at Screening (except when due to conditions for which treatment or surgery may improve VA, e.g. cataract). Ocular treatments in the study eye",
        "footnoteId": "fn_18",
        "sourceText": "8. Presence of amblyopia, amaurosis, or ocular disorders in the fellow eye with BCVA < 20/200 at Scr"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Change from Baseline in BCVA",
        "endpointType": "Primary",
        "inputs": [
          "BCVA at Week 54",
          "Baseline BCVA",
          "Alternative DR/DME treatment status"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "54 weeks"
        },
        "algorithm": "BCVA_Week_54 - BCVA_Baseline (excluding data after confounding alternative DR/DME treatments)",
        "successCriteria": "Lower limit of the two-sided 95% CI for the least square mean difference (brolucizumab - PRP) > -4 letters",
        "sourceText": "The objective related to the primary endpoint is to demonstrate non-inferiority of brolucizumab versus PRP with respect to the change from Baseline in BCVA at Week 54, assuming a non-inferiority margi"
      },
      {
        "id": "ep_2",
        "name": "First Key Secondary: Proportion of subjects with no PDR",
        "endpointType": "Secondary",
        "inputs": [
          "PDR status at Week 54"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "54 weeks"
        },
        "algorithm": "(Count of subjects with no PDR at Week 54 / Total subjects in treatment arm)",
        "successCriteria": "Superiority of brolucizumab vs PRP via CMH test (one-sided p < 0.025) after primary non-inferiority is established",
        "sourceText": "The objective related to first key secondary endpoint is to demonstrate superiority of brolucizumab versus PRP with respect to increasing the proportion of subjects with no PDR at Week 54."
      },
      {
        "id": "ep_3",
        "name": "Other Key Secondary: Proportion of subjects with center-involved DME",
        "endpointType": "Secondary",
        "inputs": [
          "Center-involved DME status up to Week 54"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Up to 54 weeks"
        },
        "algorithm": "(Count of subjects with center-involved DME / Total subjects in treatment arm)",
        "successCriteria": "Superiority of brolucizumab vs PRP via CMH test (one-sided p < 0.025) after primary and first key secondary superiority are established",
        "sourceText": "The objective related to the other key secondary endpoint is to demonstrate superiority of brolucizumab versus PRP with respect to reducing the proportion of subjects with center-involved DME up to We"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from Baseline in BCVA at Week 54",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "BCVA"
        ],
        "derivationRule": "Week 54 BCVA value - Baseline BCVA value",
        "baselineDefinition": "Last non-missing value prior to randomization/treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 54",
        "imputationRule": "ANCOVA model (Primary estimand excludes confounding effect of alternative DR/DME treatments)",
        "unit": "ETDRS letters"
      },
      {
        "id": "dv_2",
        "name": "Proportion of subjects with no PDR at Week 54",
        "variableType": "Categorical",
        "sourceVariables": [
          "ETDRS DRSS score"
        ],
        "derivationRule": "Count of subjects with DRSS score indicating no PDR / Total subjects in analysis set",
        "baselineDefinition": "Presence of PDR at Baseline as per inclusion criteria",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 54",
        "imputationRule": "Cochran-Mantel-Haenszel (CMH) test",
        "unit": "Percentage"
      },
      {
        "id": "dv_3",
        "name": "Proportion of subjects with center-involved DME up to Week 54",
        "variableType": "Categorical",
        "sourceVariables": [
          "SD-OCT anatomical markers"
        ],
        "derivationRule": "Count of subjects developing center-involved DME at any point through Week 54 / Total subjects",
        "baselineDefinition": "Absence of center-involved DME at Baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "Up to Week 54",
        "imputationRule": "null",
        "unit": "Percentage"
      },
      {
        "id": "dv_4",
        "name": "Area under the curve in change from Baseline in BCVA",
        "variableType": "Composite",
        "sourceVariables": [
          "BCVA"
        ],
        "derivationRule": "Area under the curve (AUC) calculation of change from baseline values across all visits up to Week 54 and Week 96",
        "baselineDefinition": "Last non-missing value prior to treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Up to Week 54 and Week 96",
        "imputationRule": "null",
        "unit": "ETDRS letters * weeks"
      },
      {
        "id": "dv_5",
        "name": "Change from Baseline in ETDRS DRSS score",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "ETDRS DRSS score"
        ],
        "derivationRule": "Visit_value - Baseline_value",
        "baselineDefinition": "Last non-missing score based on 7-field CFP prior to treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 54 and Week 96",
        "imputationRule": "null",
        "unit": "DRSS score units"
      },
      {
        "id": "dv_6",
        "name": "Proportion of subjects developing vision-threatening complications associated with DR",
        "variableType": "Categorical",
        "sourceVariables": [
          "Ocular complications",
          "BCVA",
          "CFP"
        ],
        "derivationRule": "Count of subjects with one or more vision-threatening complications / Total subjects",
        "baselineDefinition": "Absence of complications at Baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "Up to Week 54 and Week 96",
        "imputationRule": "null",
        "unit": "Percentage"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Baseline",
        "Treatment",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Baseline": "BASELINE",
        "Treatment": "TREATMENT",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Brolucizumab",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 6.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "6 weeks",
        "sourceText": "tients with proliferative diabetic retinopathy (PDR). Subjects who meet all the inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to one of the two treatment arms: • Brolu"
      },
      {
        "id": "dosing_2",
        "treatmentName": "RTH258",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 6.0,
            "unit": "mg"
          }
        ],
        "sourceText": "Study treatment 6.1.1 Investigational drug Table 6-1 Investigational drug Investigational Drug Pharmaceutical Dosage Form Route of Administration Supply Type Sponsor Brolucizumab 6 mg (RTH258 6 mg/ 0."
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Brolucizumab (RTH258)",
        "frequency": "Q4W",
        "route": "",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 6.0,
            "unit": "mg",
            "description": "Intravitreal injection"
          }
        ],
        "durationDescription": "96 weeks",
        "doseModifications": [
          "Dose modification and escalation details are located in Section 6.5 of the protocol."
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Panretinal Photocoagulation (PRP) Laser",
        "frequency": "Single",
        "route": "",
        "startDay": 1,
        "durationDescription": "96 weeks (study duration)"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_1",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Screening ............................................................................................................... 43 8.1.1 Information to be collected on screening failures ..................."
      },
      {
        "id": "visit_2",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Subject demographics/other baseline characteristics ............................................. 43 8.3 Efficacy ......................................................................................"
      },
      {
        "id": "visit_3",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "Safety ..................................................................................................................... 47 8.4.1 Vital sign assessments ..........................................."
      },
      {
        "id": "visit_6",
        "visitName": "EOS",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Completion",
        "sourceText": "Baseline/Day 1 visit window and timing of EOS visit for early study discontinuation. • Section 5.2 Exclusion Criteria: Protocol clarification regarding exclusion criteria Number 8, 13 and Number 20."
      },
      {
        "id": "visit_21",
        "visitName": "EOT",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "16/EOT 17/EOS Days"
      },
      {
        "id": "visit_12",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Treatment",
        "sourceText": "stable within 3 months prior to randomization and is expected to remain stable during the course of the study, as medically acceptable. •"
      },
      {
        "id": "visit_14",
        "visitName": "Week 6",
        "targetDay": 36,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "targetWeek": 6,
        "sourceText": "every 6 weeks at Baseline, Week 6 and Week 12 during the loading phase. Maintenance phase (Week 18 to Week 90): Subjects will then receive q12w injections in the maintenance phase. Additional assessme"
      },
      {
        "id": "visit_10",
        "visitName": "Week 12",
        "targetDay": 78,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": false,
        "visitNumber": 8,
        "targetWeek": 12,
        "sourceText": "PRP: initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment (may split into 2-4 sessions) as needed up to Week 90."
      },
      {
        "id": "visit_13",
        "visitName": "Week 16",
        "targetDay": 106,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 16,
        "sourceText": "had disease activity at Week 16 in a head-to-head comparison based on matched dosing intervals, with a relative decrease of 30% versus aflibercept (P = 0.0022). Significantly fewer subjects on broluci"
      },
      {
        "id": "visit_15",
        "visitName": "Week 18",
        "targetDay": 120,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "targetWeek": 18,
        "sourceText": "Maintenance phase (Week 18 to Week 90): Subjects will then receive q12w injections in the maintenance phase. Additional assessment visits are planned for disease monitoring, not for treatment administ"
      },
      {
        "id": "visit_16",
        "visitName": "Week 24",
        "targetDay": 162,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 24,
        "sourceText": "• Subjects will receive q12w injections in the maintenance phase, i.e. at Week 24, Week 36, and Week 48 in the first year. • During the maintenance phase, the additional visits (e.g. Week 30) are plan"
      },
      {
        "id": "visit_17",
        "visitName": "Week 30",
        "targetDay": 204,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 30,
        "sourceText": "• During the maintenance phase, the additional visits (e.g. Week 30) are planned for disease monitoring, not for treatment administration. However, additional injections may be administered at these v"
      },
      {
        "id": "visit_19",
        "visitName": "Week 36",
        "targetDay": 246,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "targetWeek": 36,
        "sourceText": "e.g. no new or expanding retinal neovascularization, between Week 36 and Week 48 and there was no injection at Week 42. At Week 66, the investigator may elect to further extend the treatment interval "
      },
      {
        "id": "visit_20",
        "visitName": "Week 42",
        "targetDay": 288,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 42,
        "sourceText": "and there was no injection at Week 42. At Week 66, the investigator may elect to further extend the treatment interval from 18 weeks to 24 weeks, and treat the study eye at Week 90, if the disease did"
      },
      {
        "id": "visit_9",
        "visitName": "Week 48",
        "targetDay": 330,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "targetWeek": 48,
        "sourceText": "90, with the option from Week 48 onwards to extend the treatment interval by 6 weeks at a time up to 24 weeks. •"
      },
      {
        "id": "visit_4",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "Lost to follow-up ................................................................................... 53 9.1.4 Early study termination by the sponsor ................................................. "
      },
      {
        "id": "visit_7",
        "visitName": "Week 54",
        "targetDay": 372,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "targetWeek": 54,
        "epoch": "Treatment",
        "sourceText": "change from Baseline in visual acuity at Week 54 by assessing the change from Baseline in best corrected visual acuity (BCVA) at Week 54 Secondary"
      },
      {
        "id": "visit_18",
        "visitName": "Week 66",
        "targetDay": 456,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 18,
        "targetWeek": 66,
        "sourceText": "weeks to 18 weeks and treat the study eye at Week 66, if the disease did not worsen, e.g. no new or expanding retinal neovascularization, between Week 36 and Week 48 and there was no injection at Week"
      },
      {
        "id": "visit_11",
        "visitName": "Week 90",
        "targetDay": 624,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": false,
        "visitNumber": 19,
        "targetWeek": 90,
        "sourceText": "PRP treatment (may split into 2-4 sessions) as needed up to Week 90."
      },
      {
        "id": "visit_8",
        "visitName": "Week 96",
        "targetDay": 666,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "targetWeek": 96,
        "epoch": "Treatment",
        "sourceText": "Week 96 To compare the effect of brolucizumab relative to PRP on ocular complications by assessing the proportion of subjects developing vision-threatening complications"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified block randomization",
      "centralRandomization": true,
      "blockSize": "Not specified",
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Region",
          "categories": [
            "North America",
            "Europe",
            "Asia",
            "Rest of World"
          ],
          "isBlocking": false,
          "sourceText": "region"
        },
        {
          "id": "strat_llm_1",
          "name": "Baseline BCVA",
          "categories": [
            "73 to 78 letters",
            "72 letters or fewer"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Prior anti-VEGF therapy for DME",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Novartis \nConfidential \nPage 2 \nAmended Protocol Version No. 02 (Clean) \n \nProtocol No. CRTH258D2301 \n \nTable of contents \nTable of contents ..........................................................."
    }
  }
}